Luna Musib

4.1k total citations
77 papers, 2.6k citations indexed

About

Luna Musib is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Luna Musib has authored 77 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 38 papers in Molecular Biology and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Luna Musib's work include PI3K/AKT/mTOR signaling in cancer (28 papers), Cancer Treatment and Pharmacology (23 papers) and Colorectal Cancer Treatments and Studies (17 papers). Luna Musib is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (28 papers), Cancer Treatment and Pharmacology (23 papers) and Colorectal Cancer Treatments and Studies (17 papers). Luna Musib collaborates with scholars based in United States, France and Germany. Luna Musib's co-authors include Donald Thornton, Howard A. Fine, Iris T. Chan, Ian E. Templeton, Michael Weller, Lawrence Cher, Martin J. van den Bent, Astra M. Liepa, Shengyan Hong and Alain Carpentier and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer Research.

In The Last Decade

Luna Musib

76 papers receiving 2.5k citations

Peers

Countries citing papers authored by Luna Musib

Since Specialization

Citations

This map shows the geographic impact of Luna Musib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luna Musib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luna Musib more than expected).

Fields of papers citing papers by Luna Musib

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luna Musib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luna Musib. The network helps show where Luna Musib may publish in the future.

Co-authorship network of co-authors of Luna Musib

This figure shows the co-authorship network connecting the top 25 collaborators of Luna Musib. A scholar is included among the top collaborators of Luna Musib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luna Musib. Luna Musib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 1964: Furmonertinib is a brain-penetrant EGFR TKI highly active in uncommon EGFR mutations, including PACC and exon 20 insertions 2024 ·Cancer Research ·Monique B. Nilsson, Zineb Mounir, Luna Musib, Junqin He, Xiaoxing Yu, Qing Li, (unknown), John V. Heymach, Jerry Y. Hsu, Stuart Lutzker, Xiuning Le, Marcin Kowanetz	0
2	Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study 2022 ·Targeted Oncology ·Tanya Trippett, Helen Toledano, Quentin Campbell Hewson, Arnauld Verschuur, Anne‐Marie Langevin, Isabelle Aerts, Lisa Howell, Soledad Gallego, Claudia Rössig, Amy Smith, Darshak Patel, Leonardo Pereira, Sravanthi Cheeti, Luna Musib, Katherine E. Hutchinson, Clare Devlin, Ronald J. Bernardi, Birgit Geoerger	30
3	Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib 2021 ·Cancer Chemotherapy and Pharmacology ·Vikram Malhi, Nageshwar Budha, Rucha Sane, Jian Huang, Bianca M. Liederer, Raymond D. Meng, Premal H. Patel, Yuzhong Deng, Andrés Cervantes, Josep Tabernero, Luna Musib	4
4	A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors 2020 ·Investigational New Drugs ·Geoffrey I. Shapiro, Patricia LoRusso, Daniel C. Cho, Luna Musib, Yibing Yan, Matthew Wongchenko, Ilsung Chang, Premal H. Patel, Iris T. Chan, Sandra Sanabria Bohórquez, Raymond D. Meng, Johanna C. Bendell	23
5	Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors 2019 ·Investigational New Drugs ·Geoffrey I. Shapiro, Patricia LoRusso, Eunice L. Kwak, (unknown), Charles M. Rudin, Carla Kurkjian, James M. Cleary, Mary Jo Pilat, Suzanne F. Jones, Alex de Crespigny, Jill Fredrickson, Luna Musib, Yibing Yan, Matthew Wongchenko, Hsin‐Ju Hsieh, Mary Gates, Iris T. Chan, Johanna C. Bendell	73
6	Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects 2018 ·Pharmaceutical Research ·Sravanthi Cheeti, Hao Hou, Eric Nelson, (unknown), Buyun Chen, Roland Morley, Mary Gates, Luna Musib, Sandhya Girish, Srikumar Sahasranaman, Lichuan Liu	6
7	Evaluation of Cytochrome P450 3A4-Mediated Drug–Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation 2016 ·Clinical Pharmacokinetics ·Nageshwar Budha, (unknown), Luna Musib, Steve Eppler, Mark J. Dresser, Yuan Chen, Jin Y. Jin	31
8	Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors 2015 ·Cancer Chemotherapy and Pharmacology ·Kelong Han, Jin Y. Jin, Mathilde Marchand, Stephen Eppler, Nicholas W. Choong, Stephen P. Hack, (unknown), René Bruno, Mark J. Dresser, Luna Musib, Nageshwar Budha	22
9	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study 2014 ·The Lancet Oncology ·Antoni Ribas, René González, Anna C. Pavlick, Omid Hamid, Thomas F. Gajewski, Adil Daud, Lawrence E. Flaherty, Theodore F. Logan, Bartosz Chmielowski, Karl D. Lewis, Damien Kee, Peter D. Boasberg, Ming Yin, Iris T. Chan, Luna Musib, Nicholas W. Choong, Igor Puzanov, Grant A. McArthur	201
10	Steady-State Carbamazepine Pharmacokinetics Following Oral and Stable-Labeled Intravenous Administration in Epilepsy Patients: Effects of Race and Sex 2012 ·Clinical Pharmacology & Therapeutics ·Susan E. Marino, Angela K. Birnbaum, Ilo E. Leppik, (unknown), Luna Musib, Richard C. Brundage, R. Eugene Ramsay, Page B. Pennell, James R. White, Cynthia R. Gross, John O. Rarick, (unknown), James C. Cloyd	43
11	Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma 2010 ·Journal of Clinical Oncology ·Wolfgang Wick, Vinay K. Puduvalli, Marc C. Chamberlain, Martin J. van den Bent, Alain Carpentier, Lawrence Cher, Warren Mason, Michael Weller, Shengyan Hong, Luna Musib, Astra M. Liepa, Donald Thornton, Howard A. Fine	359
12	A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas 2010 ·Neuro-Oncology ·Teri Kreisl, Svetlana Kotliarova, John A. Butman, Paul S. Albert, Lyndon Kim, Luna Musib, Donald Thornton, Howard A. Fine	81
13	A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas 2009 ·Clinical Cancer Research ·Teri Kreisl, Lyndon Kim, Kraig Moore, Paul Duic, Svetlana Kotliarova, Jennifer Walling, Luna Musib, Donald Thornton, Paul S. Albert, Howard A. Fine	40
14	Abstract #LB-256: Enzastaurin inhibits in vivo GSK3\#946; phosphorylation in early breast cancer 2009 ·Cancer Research ·Antonio Llombart‐Cussac, (unknown), (unknown), Sonia Del Barco Berrón, (unknown), (unknown), Gopinath Ganji, (unknown), (unknown), Eva Carrasco, Oluwatoyin Shonukan, Scott P. Myrand, Luna Musib, Brian P. Mullaney, Rámón Colomer	2
15	Safety of an IV formulation of carbamazepine 2009 ·Epilepsy Research ·Jeannine M. Conway, (unknown), Angela K. Birnbaum, R. Eugene Ramsay, Page B. Pennell, John O. Rarick, Luna Musib, Ilo E. Leppik, James C. Cloyd	14
16	A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer 2009 ·Annals of Oncology ·Bengt Glimelius, Michael Lahn, (unknown), Ann Cleverly, Christelle Darstein, Luna Musib, (unknown), K.-L.G. Spindler, Jan‐Erik Frödin, Åke Berglund, Per Byström, Camilla Qvortrup, Anders Jakobsen, Per Pfeiffer	22
17	Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer 2009 ·Annals of Oncology ·A.-R. Hanauske, Michael Lahn, Luna Musib, K. Weigang-Köhler, Emine Yılmaz, (unknown), Bart C. Kuenen, D. Thornton, (unknown), Giuseppe Giaccone	21
18	Phase I/pharmacokinetic study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma 2007 ·Molecular Cancer Therapeutics ·Nicholas Butowski, Kathleen R. Lamborn, Susan Chang, Margaretta Page, Jane Rabbitt, (unknown), Rupa Parvataneni, Steven J. Nicol, Luna Musib, Astra M. Liepa, Donald Thornton, Michael Prados	1
19	PD4-3-4: Correlation of pemetrexed (PEM) NSCLC exposure-response relationships (ERRs) to clinical study results from western and Japanese patient populations 2007 ·Journal of Thoracic Oncology ·Jane E. Latz, Susumu Adachi, James T. Symanowski, Kazuo Nakagawa, (unknown), Nasser H. Hanna, Michael Cullen, Christine Falcoz, Luna Musib, Hilary Calvert	6
20	Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer 2006 ·Journal of Clinical Oncology ·Michael A. Carducci, Luna Musib, Merrill S. Kies, Роберто Пили, Mylene T. Truong, Julie R. Brahmer, Patricia E. Cole, Rana Sullivan, (unknown), (unknown), Nathan Enas, Vikram Sinha, Donald Thornton, Roy S. Herbst	150

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact